Equities

ReproCell Inc

ReproCell Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)130.00
  • Today's Change1.00 / 0.78%
  • Shares traded393.30k
  • 1 Year change-46.50%
  • Beta0.8124
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year ReproCell Inc had revenues fall -17.83% from 2.95bn to 2.43bn, though the company grew net income from a loss of 305.31m to a smaller loss of 31.41m.
Gross margin48.99%
Net profit margin-7.18%
Operating margin-18.53%
Return on assets-2.03%
Return on equity-2.21%
Return on investment-2.20%
More ▼

Cash flow in JPYView more

In 2024, ReproCell Inc increased its cash reserves by 53.51%, or 1.02bn. Cash Flow from Financing totalled 544.05m or 22.42% of revenues. In addition the company used 11.45m for operations while cash from investing totalled 404.42m.
Cash flow per share-1.57
Price/Cash flow per share--
Book value per share93.57
Tangible book value per share93.31
More ▼

Balance sheet in JPYView more

ReproCell Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio10.42
Quick ratio9.99
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.